Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

featured

Published in Metastatic Breast Cancer

Expert Opinion / Cases · November 07, 2022

75yo Female With Suspected Metastatic TNBC and Suspicious Bone Metastases on Imaging but Multiple Negative Biopsies

Written by: Jing Xi MD, MPH

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Discuss This item Follow

Kristine Blake

Nov 08, 2022

Did they do biopsies CT guided?  I have lobular, and my cancer was missed for six years because they thought it was multiple myeloma. It was breast cancer, but they failed to pursue further testing. They did a bone marrow biopsy that was not CT guided and didn’t pick tissue with cancer. In 2020, I had a CT guided bone biopsy, and it was found. The cancer spread to my stomach because of the missed diagnosis.

Laura Nadeau

Nov 11, 2022
```
Did you attempt liquid biopsy? 
```

Bogdan Cristian Dinu

Nov 12, 2022

I think is not a bone metastatic disease , probably the long period of recover after two chemoterapy seances,was in liason of avascular sclerosis. Check for N telopeptide X,  oseose ALP , bone scintigraphy.

thawatchai dudsadeeprasert

Nov 20, 2022
```
Is it Paget disease of bone?
```

mehrdad payadeh

Dec 18, 2022

Due to severe 

Severe neutropenia can prepare for tightly infection and chronic osteomyelitis

Sep 28, 2023

Pending Moderator approval.
Delete

Metastatic Breast Cancer

75yo Female With Suspected Metastatic TNBC and Suspicious Bone Metastases on Imaging but Multiple Negative Biopsies

Discuss This item Follow

Kristine Blake

Laura Nadeau

Bogdan Cristian Dinu

thawatchai dudsadeeprasert

mehrdad payadeh

Further Reading

Outcomes of Neratinib + Fulvestrant + Trastuzumab and Biomarker Analysis in Patients With HR+/HER2−, HER2-Mutant MBC

Utility of a Risk-Stratification Model for Predicting Overall Survival Outcomes in Young Women With Stage IV Breast Cancer

Impact of a Bone-Targeted Therapy Regimen on Skeletal-Related Events in Patients With MBC and Bone Metastasis Surviving Longer Than 2 Years

Outcomes of ctDNA Analysis in Patients With HR+/HER2− Advanced Breast Cancer Treated With Ribociclib Plus Endocrine Therapy

Impact of First-Cycle Neutropenia and Dose Reduction on the Outcomes in Patients With HR+/HER2− MBC Treated With First-Line Palbociclib and Hormonal Therapy

Real-World Perspectives and Practices for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in HER2-Expressing Metastatic Breast Cancer

Evaluating Low HER2 Status in Invasive Breast Carcinoma via HER2 Immunohistochemistry, With HER2 FISH Correlation

Initial Pertuzumab Plus Trastuzumab ± Chemotherapy Followed by Trastuzumab Plus Emtansine for ERBB2+ Metastatic Breast Cancer

Metastatic HR+/HER2− Breast Cancer With Co-Existing ESR1 and PIK3CA Mutation

Provider and Patient Perspectives Regarding Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2− Advanced Breast Cancer

The Dynamics of HER2-Low Expression During Breast Cancer Progression

Recently Updated